Publication | Closed Access
The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
22
Citations
0
References
2016
Year
MedicineRet-dependent CancersPathologyImmune Checkpoint InhibitorTumor SuppressorCancer TreatmentOncologyCell BiologyNovel TherapyTumor Biology
No additional data available for this publication yet. Check back later!